Literature DB >> 27002787

Multiple myeloma in the marrow: pathogenesis and treatments.

Heather Fairfield1, Carolyne Falank1, Lindsey Avery2, Michaela R Reagan1,2.   

Abstract

Multiple myeloma (MM) is a B cell malignancy resulting in osteolytic lesions and fractures. In the disease state, bone healing is limited owing to increased osteoclastic and decreased osteoblastic activity, as well as an MM-induced forward-feedback cycle where bone-embedded growth factors further enhance tumor progression as bone is resorbed. Recent work on somatic mutation in MM tumors has provided insight into cytogenetic changes associated with this disease; the initiating driver mutations causing MM are diverse because of the complexity and multitude of mutations inherent in MM tumor cells. This manuscript provides an overview of MM pathogenesis by summarizing cytogenic changes related to oncogenes and tumor suppressors associated with MM, reviewing risk factors, and describing the disease progression from monoclonal gammopathy of undetermined significance to overt MM. It also highlights the importance of the bone marrow microenvironment (BMM) in the establishment and progression of MM, as well as associated MM-induced bone disease, and the relationship of the bone marrow to current and future therapeutics. This review highlights why understanding the basic biology of the healthy and diseased BMM is crucial in the quest for better treatments and work toward a cure for genetically diverse diseases such as MM.
© 2016 New York Academy of Sciences.

Entities:  

Keywords:  Fairfield, H., C. Falank, L. Avery & M. R. Reagan. 2016. Multiple myeloma in the marrow: pathogenesis and treatments. In “MARROW,” ed. by M. Zaidi. Ann. N.Y. Acad. Sci. 1364: 32-51.; bone marrow; bone marrow niche; multiple myeloma; treatments

Mesh:

Substances:

Year:  2016        PMID: 27002787      PMCID: PMC4806534          DOI: 10.1111/nyas.13038

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  234 in total

Review 1.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

2.  The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma.

Authors:  Siobhan V Glavey; Salomon Manier; Alessandro Natoni; Antonio Sacco; Michele Moschetta; Michaela R Reagan; Laura S Murillo; Ilyas Sahin; Ping Wu; Yuji Mishima; Yu Zhang; Wenjing Zhang; Yong Zhang; Gareth Morgan; Lokesh Joshi; Aldo M Roccaro; Irene M Ghobrial; Michael E O'Dwyer
Journal:  Blood       Date:  2014-07-24       Impact factor: 22.113

3.  Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.

Authors:  Murielle Roussel; Valérie Lauwers-Cances; Nelly Robillard; Cyrille Hulin; Xavier Leleu; Lotfi Benboubker; Gérald Marit; Philippe Moreau; Brigitte Pegourie; Denis Caillot; Christophe Fruchart; Anne-Marie Stoppa; Catherine Gentil; Soraya Wuilleme; Anne Huynh; Benjamin Hebraud; Jill Corre; Marie-Lorraine Chretien; Thierry Facon; Hervé Avet-Loiseau; Michel Attal
Journal:  J Clin Oncol       Date:  2014-07-14       Impact factor: 44.544

Review 4.  New understanding and treatments for osteoporosis.

Authors:  G Mazziotti; J Bilezikian; E Canalis; D Cocchi; A Giustina
Journal:  Endocrine       Date:  2012-02       Impact factor: 3.633

5.  A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma.

Authors:  Markus Hansson; Peter Gimsing; Ashraf Badros; Titti Martinsson Niskanen; Hareth Nahi; Fritz Offner; Morten Salomo; Elisabeth Sonesson; Morten Mau-Sorensen; Yvonne Stenberg; Annika Sundberg; Ingrid Teige; Jan Van Droogenbroeck; Stina Wichert; Maurizio Zangari; Björn Frendeus; Magnus Korsgren; Martine Poelman; Guido Tricot
Journal:  Clin Cancer Res       Date:  2015-02-24       Impact factor: 12.531

6.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authors:  Aldo M Roccaro; Antonio Sacco; Patricia Maiso; Abdel Kareem Azab; Yu-Tzu Tai; Michaela Reagan; Feda Azab; Ludmila M Flores; Federico Campigotto; Edie Weller; Kenneth C Anderson; David T Scadden; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2013-04       Impact factor: 14.808

7.  Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics.

Authors:  Xiao-Tao Wang; Yu-Chan He; Si-Yao Zhou; Jing-zi Jiang; Yu-Mei Huang; Yu-Zhen Liang; Yong-Rong Lai
Journal:  Leuk Res       Date:  2014-03-06       Impact factor: 3.156

Review 8.  Current strategies for treatment of relapsed/refractory multiple myeloma.

Authors:  Jacob P Laubach; Peter M Voorhees; Hani Hassoun; Andrzej Jakubowiak; Sagar Lonial; Paul G Richardson
Journal:  Expert Rev Hematol       Date:  2014-01-29       Impact factor: 2.929

9.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Authors:  Ebba Bråkenhielm; Niina Veitonmäki; Renhai Cao; Shinji Kihara; Yuji Matsuzawa; Boris Zhivotovsky; Tohru Funahashi; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

10.  Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk.

Authors:  Daniel Chubb; Niels Weinhold; Peter Broderick; Bowang Chen; David C Johnson; Asta Försti; Jayaram Vijayakrishnan; Gabriele Migliorini; Sara E Dobbins; Amy Holroyd; Dirk Hose; Brian A Walker; Faith E Davies; Walter A Gregory; Graham H Jackson; Julie A Irving; Guy Pratt; Chris Fegan; James Al Fenton; Kai Neben; Per Hoffmann; Markus M Nöthen; Thomas W Mühleisen; Lewin Eisele; Fiona M Ross; Christian Straka; Hermann Einsele; Christian Langer; Elisabeth Dörner; James M Allan; Anna Jauch; Gareth J Morgan; Kari Hemminki; Richard S Houlston; Hartmut Goldschmidt
Journal:  Nat Genet       Date:  2013-08-18       Impact factor: 38.330

View more
  49 in total

Review 1.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

2.  Conventional Cytogenetics and Interphase Fluorescence In Situ Hybridization Results in Multiple Myeloma: A Turkey Laboratory Analysis of 381 Cases.

Authors:  Cigdem Aydin; Turgay Ulas; Ceren Hangul; Orhan Kemal Yucel; Utku Iltar; Ozan Salim; Deniz Ekinci; Sibel Berker Karauzum
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-25       Impact factor: 0.900

3.  Development of a 3D bone marrow adipose tissue model.

Authors:  Heather Fairfield; Carolyne Falank; Mariah Farrell; Calvin Vary; Joshua M Boucher; Heather Driscoll; Lucy Liaw; Clifford J Rosen; Michaela R Reagan
Journal:  Bone       Date:  2018-01-31       Impact factor: 4.398

4.  The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Authors:  F Fan; M H Bashari; E Morelli; G Tonon; S Malvestiti; S Vallet; M Jarahian; A Seckinger; D Hose; L Bakiri; C Sun; Y Hu; C R Ball; H Glimm; M Sattler; H Goldschmidt; E F Wagner; P Tassone; D Jaeger; K Podar
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

5.  Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical Trial.

Authors:  Ajay K Nooka; Michael Luhua Wang; Andrew J Yee; Jonathan L Kaufman; Jooeun Bae; Doris Peterkin; Paul G Richardson; Noopur S Raje
Journal:  JAMA Oncol       Date:  2018-12-13       Impact factor: 31.777

6.  Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination.

Authors:  Ilseyar Akhmetzyanova; Mark J McCarron; Samir Parekh; Marta Chesi; P Leif Bergsagel; David R Fooksman
Journal:  Leukemia       Date:  2019-08-22       Impact factor: 11.528

Review 7.  Tissue engineered models of healthy and malignant human bone marrow.

Authors:  Alan Chramiec; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2019-04-17       Impact factor: 15.470

8.  Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNFα.

Authors:  Ilseyar Akhmetzyanova; Tonya Aaron; Phillip Galbo; Anastasia Tikhonova; Igor Dolgalev; Masato Tanaka; Iannis Aifantis; Deyou Zheng; Xingxing Zang; David Fooksman
Journal:  Blood Adv       Date:  2021-09-28

Review 9.  Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.

Authors:  Cristina Sobacchi; Eleonora Palagano; Anna Villa; Ciro Menale
Journal:  Front Bioeng Biotechnol       Date:  2017-05-17

10.  EPS8-mediated regulation of multiple myeloma cell growth and survival.

Authors:  Honghao Zhang; Lijuan Zhou; Weijun Zhou; Xiaoling Xie; Meirong Wu; Yiran Chen; Yuxing Hu; Jingwen Du; Yanjie He; Yuhua Li
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.